<div id="readability-page-1">10:29 AM EST, 12/01/2025 (MT Newswires) -- Lenz Therapeutics ( LENZ ) and Lotus Pharmaceutical said Monday that Lotus submitted a new drug application to South Korea's Ministry of Food and Drug Safety for Vizz to treat presbyopia in adults.The submission was supported by data from phase 3 trials in the US in which Vizz met all primary and secondary near vision improvement endpoints, the companies said.Under the May 2025 license and commercialization agreement, Lenz Therapeutics ( LENZ ) is eligible to receive up to $125 million in regulatory and commercial milestone payments along with tiered, double-digit royalties on future net sales, according to the companies.Shares of Lenz Therapeutics ( LENZ ) were down over 1% in recent trading.Price: 29.72, Change: -0.80, Percent Change: -2.63 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

LENZ

Lenz Therapeutics 和 Lotus Pharmaceutical 已向韓國食品藥品安全部提交了 Vizz 的新藥申請，該藥物用於治療老花眼。該申請得到了美國成功的三期臨牀試驗數據的支持。Lenz Therapeutics 可能會獲得高達 1.25 億美元的里程碑付款和版税。Lenz 的股價下跌超過 1%，交易價格為 29.72 美元

LENZ Therapeutics 和 Lotus Pharmaceutical 表示，治療老花眼的新藥申請已在韓國提交